Join Rectify Pharma for a virtual R&D event on Thurs. Nov. 21 at 11am ET, featuring key opinion leaders who will discuss unmet needs in hepatobiliary diseases, how its lead development candidate RTY-694 is advancing to the clinic, and how Rectify’s small molecule positive functional modulator (PFM) offers a differentiated approach to address the core pathophysiology of primary sclerosing cholangitis and multiple hepatobiliary diseases. Register here: https://lnkd.in/gQaGHrmg
LifeSci Advisors, LLC
金融服务
New York,New York 15,393 位关注者
Accelerating Innovations In Life Science.
关于我们
LifeSci Advisors is a unique investor relations consultancy founded to provide companies in the life sciences field with a comprehensive solution to investor communications and outreach. Our services are designed to increase our clients’ visibility within the investment community and to educate investors about the opportunity. We strive to effectively communicate each clients’ unique value proposition, building momentum for the investment. We begin with deep due diligence as we partner with each client to gain an unparalleled level of understanding of their business and the opportunities they are addressing. This in-depth knowledge allows us to be able to provide each client partner with thoughtful recommendations related to corporate communications, investor outreach, and capital markets planning. Our strategies and actions are specifically tailored to help each client achieve their investor relations goals.
- 网站
-
https://www.lifesciadvisors.com
LifeSci Advisors, LLC的外部链接
- 所属行业
- 金融服务
- 规模
- 51-200 人
- 总部
- New York,New York
- 类型
- 私人持股
- 创立
- 2009
- 领域
- Investor Relations
地点
-
主要
250 W 55th St
#3401
US,New York,New York,10019
LifeSci Advisors, LLC员工
动态
-
Join Grace Therapeutics, Inc. (#GRCE) for a virtual KOL event on Wed, Nov. 20 at 2pm ET, featuring Abhishek Ray, MD (University Hospitals) and Andrew Webb, PharmD, BCCCP (Massachusetts General Hospital), who will discuss the high unmet medical need and current treatment landscape for patients suffering from aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency. Register here: https://bit.ly/3YBk4Mn
-
Join Helio Genomics on Mon, Nov. 18 at 5pm PT for an exclusive evening of networking & cocktails with company management at #AASLD The Liver Meeting in San Diego. Chief Medical Advisor, Richard Van Etten, MD, PhD, will be present to discuss Helio’s CLiMB trial, recent data on its methylation model for tumor aggressiveness, and other pipeline products for liver cancer. Register here: https://bit.ly/3Al4EE4
-
Don't miss it! Tune into the virtual KOL event hosted by Adaptimmune (#ADAP) on Mon, Nov. 18 at 2:30 pm ET, featuring Dr. Sandra P. D’Angelo, M.D. (Memorial Sloan Kettering Cancer Center) who will discuss the current treatment landscape for patients with sarcoma. Register here: https://bit.ly/3Aeh2FY
-
Join INmune Bio Inc. (#INMB) for a virtual KOL event on Thurs, Nov. 7 at 1pm ET featuring Prof. Judith Jaeger, PhD, MPA and Sarah Barnum, PhD, ABPP from CognitionMetrics who will join CJ Barnum, PhD, VP of CNS Drug Development, to discuss the unmet need and current treatment landscape for patients with Early Alzheimer’s Disease (AD) with biomarkers of elevated neuroinflammation. Register here: https://bit.ly/48u8mYF
-
Join us on Thursday, November 14th at 12:30pm ET for the latest "Lunch with LifeSci" webinar featuring Compass Therapeutics Inc. (#CMPX). CEO Thomas Schuetz, MD, PhD will discuss the development of their innovative bispecific antibody, CTX-009, a dual-targeting therapy designed to block tumor growth and progression in patients with biliary tract cancer (BTC). Register here: https://bit.ly/3YrDzXS
-
Join Vera Therapeutics, Inc. (#VERA) for a virtual investor event TOMORROW, Oct. 28 at 8 am ET, featuring Jonathan Barratt, MD, PhD, FRCP (University of Leicester), along with Vera’s management team, who will discuss long-term data from the Phase 2b ORIGIN trial of atacicept in immunoglobulin A nephropathy (IgAN), showing atacicept stabilized kidney function through 96 weeks. Register here: https://bit.ly/4hnZPdW
-
Join Humacyte (#HUMA) for a virtual KOL event with a Q&A session on Thurs, Oct. 31 at 8am ET, featuring Charles Keith Ozaki, MD (Brigham and Women’s Hospital), Mohamad Anas Hussain, MD, PhD (Brigham and Women’s Hospital), and Timmy Lee, MD, MSPH (University of Alabama at Birmingham), who will discuss the current treatment landscape and unmet need for improved arteriovenous (AV) access in hemodialysis patients. Register here: https://bit.ly/3UlIOae
-
Tune into the Inmagene Biopharmaceuticals virtual KOL event on Thurs, Oct. 31 at 10am ET with Jonathan Silverberg, MD, PhD, MPH, Maryanne Senna, MD, and Yufang Lu, MD, PhD, who will discuss the potential role of anti-OX40/OX40L monoclonal antibodies (mAbs) in the treatment of atopic dermatitis (AD) and alopecia areata (AA). Register here: https://bit.ly/4esqDYt
-
Join Pharvaris (#PHVS) for a virtual investor event on Weds, Oct. 23 at 10am ET featuring Michael Manning, M.D. (Allergy, Asthma & Immunology, LTD) and Raffi Tachdjian, M.D., MPH (David Geffen School of Medicine at the University of California, Los Angeles), who will join company management to discuss the unmet medical need and current treatment landscape for hereditary angioedema (HAE) attacks and other bradykinin-mediated diseases. Register here: https://bit.ly/3BQ95qP